The Cooper Companies, Inc.

COO • Medical - Instruments & Supplies

$69.59

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 ene 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$13.69B

Crecimiento

3.1%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 9.2%Crecimiento positivo de ingresos · 8.4%Flujo de caja libre positivo · 2.17Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.34

Datos financieros hasta: 31 ene 2026, 12:00 a.m. UTCÚltima actualización de earnings: 5 mar 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$69.59

Change0.00%

Shares Out196.70M

Market Cap$13.69B

Enterprise Value$16.06B

52W Range58.89 - 89.83

Beta0.87

P/E34.10

P/S3.30

P/B1.64

P/FCF27.87

EV/Sales3.87

Price$69.59

Change0.00%

Shares Out196.70M

Market Cap$13.69B

Enterprise Value$16.06B

52W Range58.89 - 89.83

Beta0.87

P/E34.10

P/S3.30

P/B1.64

P/FCF27.87

EV/Sales3.87

EV/EBITDA16.70

EV/FCF32.70

Earnings Yield2.93%

FCF Yield3.59%

Dividend Yield0.00%

Gross Margin60.67%

Oper. Margin16.69%

Profit Margin9.16%

Debt/Eq0.34

Current Ratio1.89

Quick Ratio1.13

Revenue 5Y3.15%

Target$76.80

Target Upside10.36%

Target Median$85.00

Target Range61.00 - 86.00

Volume8.81M

Avg Volume2.36M

EPS Surprise0.11

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

59/100

Fortaleza financiera

Deuda, caja, estabilidad

83/100

Potencial de crecimiento

Ingresos y expansión

53/100

Atractivo del precio

Barata o cara hoy

59/100

Por qué este puntaje▼

Márgenes estables o en mejora · 9.2%Crecimiento positivo de ingresos · 8.4%Flujo de caja libre positivo · 2.17Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.34Liquidez saludable · 1.89

Analyst view

Analyst sentiment and price target

COO

Analyst sentiment

Based on 25 analyst votes · 2026-09-05

80/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-05

Bajo

$61.00

Promedio

$80.33

Mediana

$85.50

Alto

$98.00

Resumen de la compañía

IPO: 1/21/1983

Industria: Medical - Instruments & Supplies

P/B i: 1.64

Deuda / Patrimonio i: 0.34

Margen operativo: 16.69%

Margen neto: 9.16%

ROE i: -

ROIC: -

Salud financiera

Puntaje17 / 20

Deuda / Patrimonio: 0.34

Ratio corriente: 1.89

Ratio rápido: 1.13

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Rosebrough Walter M Jr

Transacción: 04/01/2026

VENTA

Cambio

-832

Precio

Not reported

Presentación

04/21/2026

Tipo

VENTA

Rosebrough Walter M Jr

Transacción: 04/01/2026

COMPRA

Cambio

+832

Precio

Not reported

Presentación

04/21/2026

Tipo

COMPRA

Rosebrough Walter M Jr

Transacción: 01/03/2026

COMPRA

Cambio

+832

Precio

Not reported

Presentación

04/21/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Rosebrough Walter M Jr	VENTA	-832	Not reported	04/01/2026	04/21/2026
Rosebrough Walter M Jr	COMPRA	+832	Not reported	04/01/2026	04/21/2026
Rosebrough Walter M Jr	COMPRA	+832	Not reported	01/03/2026	04/21/2026
Kurzius Lawrence Erik	VENTA	-3,322	Not reported	04/01/2026	04/06/2026
Kurzius Lawrence Erik	COMPRA	+3,322	Not reported	04/01/2026	04/06/2026
Lucchese Cynthia L	VENTA	-3,322	Not reported	04/01/2026	04/06/2026
Lucchese Cynthia L	COMPRA	+3,322	Not reported	04/01/2026	04/06/2026
MADDEN TERESA S	VENTA	-3,322	Not reported	04/01/2026	04/06/2026
MADDEN TERESA S	COMPRA	+3,322	Not reported	04/01/2026	04/06/2026
Rosebrough Walter M Jr	COMPRA	+3,779	Not reported	04/01/2026	04/06/2026
Carbone Barbara	COMPRA	+3,050	Not reported	04/01/2026	04/06/2026
Carbone Barbara	VENTA	-3,050	Not reported	04/01/2026	04/06/2026
Jay Colleen	VENTA	-3,322	Not reported	04/01/2026	04/06/2026
Jay Colleen	COMPRA	+3,322	Not reported	04/01/2026	04/06/2026
Rivas Maria	COMPRA	+3,322	Not reported	04/01/2026	04/06/2026
Rivas Maria	VENTA	-3,322	Not reported	04/01/2026	04/06/2026
WEISS ROBERT S	VENTA	-3,654	Not reported	04/01/2026	04/06/2026
WEISS ROBERT S	COMPRA	+3,654	Not reported	04/01/2026	04/06/2026
McCuin Robert	OTRO	+14,109	$5.69	02/18/2026	02/27/2026
McCuin Robert	OTRO	+641,025	Not reported	02/18/2026	02/27/2026

Sobre la compañía

The Cooper Companies, Inc.

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Fuente - Link

Competidores

DOCS FMS HOLX ICLR NBIX SMMT SNN SOLV TEM UHS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Countdown to The Cooper Companies (COO) Q3 Earnings: Wall Street Forecasts for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for The Cooper Companies (COO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

Zacks Investment Research

Dell Technologies Inc (DELL) (Q2 2026) Earnings Call Highlights: Record Revenue and AI Backlog Fuel 203% EPS Surge

Revenue: Record revenue of $47 billion, up 58% year-over-year.Earnings Per Share (EPS): Record diluted non-GAAP EPS of $7.04, up 203%.Gross Margin: Gross margin

GuruFocus

Unity Software COO Alexander Blum Sells 22,559 Shares for $1 Million

The transaction involved 22,559 shares with a total estimated value of ~$1.0 million based on weighted average pricing. The sale represented 3% of the total equity holdings held directly by the executive prior to this filing.

The Motley Fool

Rigetti Computing's COO Sells Over 9,000 Company Shares. What Does That Mean for Investors?

The disposal of 9,038 shares was executed at a weighted average price of $16.79 per share, totaling ~$152,000. The transaction reduced the insider's direct equity position by 3% of previous holdings.

The Motley Fool

COO vs. MMSI: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-06-04	1.1	1.21	0.11
2026-03-05	1.03	1.1	0.07
2025-12-04	1.11	1.15	0.04
2025-08-27	1.07	1.1	0.03
2025-05-29	0.928	0.96	0.032
2025-03-06	0.914	0.92	0.006
2024-12-05	1	1.04	0.04
2024-08-28	0.911	0.96	0.049
2024-05-30	0.829	0.85	0.021
2024-02-29	0.783	0.85	0.067
2023-12-07	0.87	0.87	0
2023-08-30	0.84	0.84	0